Putting YOU First

2015 PROGRESS REPORT
There are several risk factors for prostate cancer, including family history, age and race. Know your risks for prostate cancer and talk to your doctor about early detection and screening.

PCF is changing. We are augmenting our reach to a global mass audience that includes men on their prostate cancer journey along with their family, friends and the communities that surround them. Our patient-centric goal—Putting YOU First—is to reach those who need us most: brothers, fathers, sons, mothers, daughters, and sisters.

As we move forward, 2016 is full of new possibilities. We are excited to see how these landmark discoveries will impact patients and how the field will grow to solve this disease for good.

PCF prostate cancer doctors and scientists have gotten a glimpse of what the finish line looks like, and it is precision medicine—tailoring treatment after re-biopsy to individual patients’ unique disease and then targeting their specific molecular alterations any time the disease comes out of remission. PCF: Putting YOU First.
Founder & CEO Letter 4
Top 5 Discoveries of 2015 Mean More Lives Saved in 2016 7
New Clinical Trial Methods Accelerating Research and Development 11
Prostate Cancer Patients: Yesterday, Today ... Tomorrow 13
My Prostate Cancer Story: Muhit Rahman 19
PCF & MLB Step Up to the Plate 20
Friends of PCF Make a Difference: Leveraging Relationships and Passion into Research Dollars 22
A Survivor’s Appeal for Support 26
Supporting Cures 27
2015 Donor Roll 28
2015 Research Awards: Expanding PCF’s Global Research Enterprise 34
2015 Financials 38
2015 PCF Supporting Partners 42
Board of Directors and Leadership Team 43
Dear Friends,

One million four-hundred thousand. That’s how many more men are alive today than was projected when we founded PCF. Enough to fill 28 Yankee Stadiums. One of us is among that fortunate group.

Ninety-nine. That’s the percentage of American men diagnosed with prostate cancer today who can expect to survive beyond the all-important five-year mark.

Because of your support over the years—and because of the leverage we’re able to obtain from follow-on biopharma investments and research grants—PCF has been involved with every major breakthrough of the past two-plus decades. On behalf of patients and their loved ones everywhere, thank you for that support.

Because of the investments made with that support, 2015 will be remembered as the year precision oncology for advanced prostate cancer became reality. Precision oncology is transforming cancer care by predicting which treatments will be most effective based on the molecular changes in each patient’s cancer. The landscape of genetic mutations that occur in lethal prostate cancers was unmasked for the first time in 2015 by the PCF International Prostate Cancer Dream Team. They discovered 17 targets that can be exploited with new and existing FDA-approved drugs used for other cancers. Currently, first-in-field treatments are working their way through the clinical trial pipeline for 11 of these 17 “precision oncology targets.” We’re committed to channeling more resources to team science that will tackle all 17.

Thanks to these discoveries, we’re rapidly approaching the day when a simple blood test will allow a doctor to write a precision prescription. The patient will be treated with the right medicine precisely at the right time. The result: more permanent remissions for men with the worst forms of prostate cancer. Perhaps even more exciting is that this research shows how the prostate cancer “precision prescription pad” will result in game-changing new treatments for breast, ovarian, lung, colon, and brain cancers, as well as other chemotherapy-resistant human cancer types. The bottom line: more lives saved.

More than ever, advances against one form of cancer may translate to treatments for other types, as we begin to understand cancer by its
unique genetic fingerprint rather than by where it arises anatomically. A precision treatment that’s effective for certain types of prostate cancer, for instance, cures all colon cancers that are driven by the same pathway. The same is true for specific breast and lung cancer mutations as well as for some children’s cancers. So while we’re still laser-focused on prostate cancer, the work we support increasingly benefits all cancer patients.

**Getting the Word Out**

Much of our work is focused on treatments and cures, but if we can use public health programs to help men avoid getting prostate cancer altogether, that’s even better. One of the simplest and most effective means of reducing prostate cancer deaths is convincing men to get screened—particularly those men at higher risk.

In 2015, PCF partnered with former world heavyweight champ Evander Holyfield and sportscaster Brian Custer for a series of public service announcements encouraging men to “Man Up, Get Checked.” Holyfield and Custer were featured in a new public service announcement and a special print and digital supplement in USA Today. Combined, these efforts reached an estimated 144 million viewers and readers. Even a modest conversion rate would yield thousands of men whose lives are saved or extended because they heard the call to action to get screened.

**Looking to the Future**

Under the leadership of PCF Board member Andy Astrachan, we’re launching an exciting new initiative tentatively titled the Movement. We’ve always worked to share essential treatment information directly with patients so they can be proactive. Now, a newly redesigned patient-facing PCF website (along with new mobile apps) will give anyone in the world with a connected device the ability to access the “PCF Brain.” Information will be communicated in a way that’s easy for patients and home caregivers to understand, and the application will allow patients to talk to their doctors about precision Rx clinical trials, genetic counseling and optimal nutrition and exercise regimens.

The Movement is also a rallying tool to help us finally eliminate prostate cancer as a cause of death. Aimed directly at 14 million prostate cancer patients and those who love and support them, the PCF-led initiative will be the largest and most powerful patient community ever assembled for any disease. Using technology to connect, information to unite, and motivational messaging and communications to inspire, the Movement aims to harness the immense collective power of prostate cancer patients and their
loved ones. Movement members will share and regularly receive crucial information from PCF, advocate for PCF, and crowdfund $1 billion or more to PCF-led research.

As the originators of team science, we continue to advance interdisciplinary research among our own investigators and across other disease areas. Given the wide applicability of our work to other forms of cancer, we’re recruiting researchers with different primary areas of focus, including lung, colon, ovarian, breast, and bladder cancer specialists. They’ll work with us on developing new treatments that target shared precision oncology targets—that is, the genetic vulnerabilities of cancer.

This report should make it clear that we’re in the midst of a research renaissance with limitless possibilities, and prostate cancer patients today have more reason to be hopeful than at any time in history.

The founding of PCF in 1993—and the continuing generous support of our donors—has been an essential reason why the prostate cancer death rate has decreased by more than 50%. But it’s not just about the 14 million men living with the disease now. It’s also about the innumerable men in future generations who will never have to think about prostate cancer as a lethal disease, about patients suffering from all cancers, and about their loved ones.

We’re so close, but until we have solutions for all patients, our work is not done.

As always, we thank you for your support.

Sincerely,

Michael Milken
Founder and Chairman

Jonathan W. Simons, MD
President and Chief Executive Officer
David H. Koch Chair
A Great Leap Forward

While every year brings new discoveries and greater understanding, 2015 stands out as an exceptional year for science. And not just science—genetics-based science that will, in the very near future, directly affect the care and improve the outcome for thousands, if not millions, of prostate cancer patients worldwide. Not since we reported the approval of six new drugs in just four years in 2013 are we seeing the potential for more lives lived longer, better, and more fully. What’s most exciting is that PCF’s efforts to treat prostate cancer precisely according to its myriad genetic profiles is helping to decipher other genetically complex diseases that have challenged traditional therapeutic approaches. By the end of the year, PCF came to stand for “Precision Cures” Foundation for all human cancer.

Of 9,656 research papers published in 2015, five dominate with research results for patients. Significantly, all of these were funded by PCF and represent a total investment of $9.6 million.

1. Complete Genomic Landscape of Prostate Cancer Mapped

In 2012 PCF provided funding to the East Coast-International Prostate Cancer “Dream Team,” led by Arul Chinnaiyan, MD, PhD (University of Michigan), and Charles Sawyers, MD (Memorial Sloan Kettering Cancer Center), to analyze the genetic profiles of 150 advanced prostate cancer tumors. Despite the enormous scope of this proposed work, the anticipated results promised an unprecedented look at this lethal disease.

Just three short years later, the team unveiled a complete digital image of prostate cancer to the world. Described as the tumor’s genomic landscape, these results identified 17 new molecular targets that may be our best weapon in the fight for permanent remissions. In many ways, these 14 new targets set the entire agenda for the prostate cancer biopharma industry.

This work is highly significant in that it holds the potential to tell doctors precisely who to treat and how they should be treated. Doctors have
long recognized that prostate cancer is not a single disease, and that its variations are associated with a wide variety of outcomes. However, with only a microscopes to guide them, there was no way for doctors to match a patient to his optimal treatment. Leveraging recent advances in biotechnology—which permit the relatively rapid and cost-effective characterization of tumors’ genetic profiles—the Dream Team has effectively smashed the “one-size-fits-all” treatment paradigm that has prevailed in the clinic for decades.

This work stands to dramatically improve the care of all prostate cancer patients. The Dream Team’s results mean that if a doctor were to biopsy a tumor, there would be nearly a 90% chance that there would be something actionable—“treatable”—in its DNA. The doctor could then write a precision prescription for the most effective course of treatment, whether FDA-approved or experimental.

2 Resolving Health Disparities in Prostate Cancer: New Signatures Identified

In 2015, discoveries in prostate cancer genetics helped us better understand the disproportionate disease burden carried by African-American men, who are 70% more likely to develop prostate cancer than any other race or ethnicity, and 2.4 times more likely to die from the disease. A pioneering study by PCF Young Investigator Kosj Yamoah, MD, PhD (Moffitt Cancer Center), identified six new gene biomarker signatures of aggressive disease in African-American men with prostate cancer. These findings, published in the September 1st issue of the Journal of Clinical Oncology, shed much-needed light on the biological factors that predispose African-American men to early, aggressive disease, and provide important targets for future drug development.

This major breakthrough carries with it a new, unanticipated problem: we don’t know the function of most of these genes. In order to address this inequality, we need to get basic science on the function of these genes funded. It is time to invest resources strategically in this arena and solve this disparity for good.

3 Key Mechanism of Metastasis Discovered

When considering prostate cancer genomics, there is nothing more significant than identifying new vulnerabilities in the disease—targets that can be exploited with new drugs to put patients into lasting remissions. A team of researchers led by Karen Knudsen, PhD (Thomas Jefferson University), has done just that—their studies revealed that a
single molecule called DNA-PK drives cancers from being a slow-growing, benign disease into a killer.

Under normal conditions, DNA-PK, along with half a dozen other molecules, helps to combat routine DNA damage. However, Dr. Knudsen’s team, funded in part by the Movember Foundation and the Edward P. Evans Foundation, found that it also helps cancer cells evade many forms of treatment. In men with prostate cancer, they discovered, DNA-PK molecules are recruited by the androgen receptors (AR), which are responsible for feeding male hormones to tumor cells, allowing these mutated cells to survive. By identifying DNA-PK as a key mechanism of metastasis, the team’s research has enormous clinical implications for rationally designed new precision drugs.

4 Treating BRCAness Precisely

In a landmark clinical trial, a new class of cancer drug—originally approved in 2013 for women with rare, inherited forms of breast and ovarian cancer—proved extraordinarily effective in treating men with certain types of chemotherapy- and hormone therapy-resistant prostate cancer. **This clinical trial is a major milestone as it is the first study to show the benefit of precision medicine in prostate cancer.** The oral drug, olaparib from AstraZeneca, halted tumor growth in 88% of prostate cancer patients with defective BRCA genes, a condition that affects roughly 30% of men with the disease. Even more promising, the drug was also found to benefit many patients who did not harbor BRCA mutations. These exciting findings were published in a PCF-driven report in the *New England Journal of Medicine* in October. Now PCF is catalyzing a U.K.-U.S. group in partnership with AstraZeneca to do the Phase III trial to secure Breakthrough FDA Designation for olaparib. Plus, we plan to expand R&D on other DNA damage repair drugs, which may work even better than olaparib, in 2016. In North Carolina, one patient with BRCA-mutated prostate cancer, Richard Mackey, reached out to PCF to share his story on how olaparib gave him a new lease on life after all of his other treatment options had been exhausted.

5 Exercise and Healthy Habits Decrease Prostate Cancer Risk

Even with the most sophisticated analyses, genes alone cannot predict with complete certainty if a man will develop prostate cancer in his lifetime. This is why living a healthy lifestyle is imperative. **A new study by Stacey Kenfield, ScD, and June Chan, ScD (University of California, San Francisco), has found that vigorous exercise and other healthy habits may cut a man’s chances of developing lethal prostate cancer by up to 68%.** While we have always been aware of the benefits of exercise and nutrition, we now know that they have a direct impact on a man’s
prostate health. Not only that, but the same habits that can stave off prostate cancer development and recurrence may also prevent other age-related illnesses including heart disease and diabetes. These findings are especially relevant for older (age 60+) men, men with a family history of prostate cancer, or African-American men, for whom the value of a healthy lifestyle, including a nutritious diet and plenty of exercise, cannot be overstated.

Partners in Precision
These game-changing discoveries would not be possible without the support and dedication of our friends at the Movember Foundation. Since 2007, the Movember Foundation has generously donated $44 million to PCF to support 33 research awards in the U.S., Canada and the U.K. Movember-funded awards have generated actionable data and enabled the discovery of novel tools to better diagnose the disease earlier and generate precision treatment strategies for new, targeted medicines for advanced prostate cancer. Over the last decade, the Movember Foundation has emerged as an iconic symbol of advancing men’s health issues on a global scale, and PCF is forever grateful for this valued partnership.

Future Directions
The totality of this work shows, without question, that an investment in PCF means faster and more precise solutions for not just prostate cancer, but for all cancers that claim 580,000 American lives each year. In 2015 we made the fundamental discovery that curing some prostate cancers means cures for 100% of WNR-driven colon cancer patients. BRCA1/1 PALB-driven breast cancer patients will likewise get better drugs from prostate cancer treatment research and development. Soon, all p53 mutant lung cancer patients may get prostate cancer precision medicines. Effective drugs for ETS-driven childhood cancers may come from PCF, and redeployment of prostate cancer precision immunotherapy research biotechnology may treat any form of human malignancy. This means that, in the near future, a physician will be able to biopsy any patient’s tumor and write a precision prescription that matches his exact molecular profile.

With these exciting new data, we can say with much certainty that 2015 was a landmark year for the Foundation. It was also completely unlike any other in 113 years of academic urology. With genomic precision we now can see the path to conquering prostate cancer as a fatal disease. We have made seminal progress this year in changing the future of the precision practice of prostate cancer oncology. All this goes to show that after two decades, PCF remains the best investment in a cure.
Prostate cancer can be slow to progress, frustrating the development of new therapies for patients with early, high-risk disease. New results from ICECaP (Intermediate Clinical Endpoints for Cancer of the Prostate), a PCF-supported initiative led by Dr. Christopher Sweeney, will cut the time required to assess new therapies for aggressive prostate cancer by 50%. Dr. Sweeney and his team identified a new clinical trial endpoint that will shorten the time taken to conduct trials, enabling the development of novel therapies that can be administered at the earliest—and potentially most curative—stage possible.

“We need to move trials for new precision therapies earlier, as this is the time when patients with lethal but potentially curable cancer have the best chance of being cured,” said Dr. Sweeney, who is a medical oncologist at the Dana-Farber Cancer Institute and Associate Professor in Medicine at Harvard Medical School. “We already have many new treatments that extend the lives of patients in the late-stage metastatic setting but aren’t curative. If we can use them earlier, it is likely we can improve upon proven successes in the adjuvant setting.”

When diagnosed early, prostate cancer is highly treatable, but approximately 20% of patients will experience disease recurrence. However, because of the slow nature of prostate cancer progression, it can take 10-15 years before patients who relapse succumb to the disease. Of the approximate 26,000 deaths per year in the U.S. resulting from prostate cancer, an estimated 17,000 are patients initially diagnosed with localized disease who ultimately experienced progression.

Finding ways to prevent recurrence in these patients would pay enormous dividends toward reducing deaths from prostate cancer. Unfortunately, only a fraction of clinical trials for new therapies are conducted in patients presenting
with localized disease. The overwhelming majority of trials are in recurrent or metastatic prostate cancer, when patients are essentially incurable.

The dearth of trials in early prostate cancer stems from the difficulty of conducting them. In order for international regulatory agencies such as the FDA to approve a new therapy, an improvement in length or quality of life resulting from the therapy must first be demonstrated in clinical trials. The “overall survival” (OS) endpoint, which measures the length of time from randomization to death from any cause, is the gold standard for measuring the impact of a treatment on length of life. In localized prostate cancer, reaching an OS endpoint can require 10-15 years—a prohibitive timeframe for pharmaceutical companies. This fact has translated into only limited improvements having been made in the treatment of early, aggressive prostate cancer in the last decade.

PCF identified this issue as a critical unmet need, and in 2012 supported the establishment of the ICECaP Working Group, funded in partnership with Astellas/Medivation, Janssen, Millennium/Takeda, Sanofi and Sotio. The goal of ICECaP is to undertake the arduous task of identifying an intermediate clinical trial endpoint that functions as a “surrogate” for OS. A successful surrogate would accurately predict overall survival but could be obtained much earlier in the course of the disease. The information on the surrogate endpoint would then be forwarded to regulatory agencies and drug companies around the world to hasten clinical trials and regulatory approvals for new therapies for early prostate cancer patients.

To accomplish this goal, the team assembled data from 21,140 patients from 24 randomized clinical trials in early-stage prostate cancer for which long-term clinical follow-up information was available. A statistical analysis plan was created in which a candidate surrogate endpoint was required to meet two conditions to be considered suitable: 1) the surrogate must correlate with the true endpoint (e.g., overall survival), and 2) the effects of the treatment on overall survival and on the surrogate endpoint must be correlated (e.g., the treatment must affect both endpoints to similar degrees).

The group found that “disease-free survival” (DFS) rates at five years (a measure of the length of time from randomization until local/regional progression, distant metastasis, or death from any cause) significantly correlated with overall survival rates at eight years (correlation of 0.86). In addition, the treatments were found to similarly affect the OS and DFS endpoints (correlation of 0.73). (A correlation value of 0.70 or greater is considered a reliable surrogate.)

“We are providing the information which regulatory authorities will be able to use as documentation that disease-free survival is a strong surrogate for overall survival. We are currently also assessing the more refined endpoint of metastasis-free survival as a surrogate for overall survival and will present the results of this analysis later in 2016,” Dr. Sweeney said. “This project will inform drug developers on how to design their studies. They will then use this to petition regulatory authorities to see if it meets their metrics for approval.

“Although our work is not yet done, we have completed the most difficult task of collecting the data as part of a magnificent and inspiring data-sharing collaboration. I am confident the final product will be able to guide the next generation of clinical trials,” said Dr. Sweeney. “This will help us to more expediently evaluate new therapies and apply all of the advancements we’ve been making in drug development to decreasing the death rate from prostate cancer.”
Over the last two decades, the death rate from prostate cancer has declined more than 50%. In itself, this is a monumental accomplishment that can be attributed to a constellation of factors including earlier detection, improved treatments, and better access to care—especially among underserved communities. But this large-scale trend also raises an important question: what, if anything, has changed for the individual patient on his prostate cancer journey?

Of course, just as each prostate tumor is biologically unique, so too each patient’s journey represents a singular experience. But how does each generation of advances in medicine and technology translate to the patient experience, beyond these broader trends in survival? Moreover, what do these advances mean for men and their families today, and how is this different from the experience of their fathers and grandfathers before them? And finally, what does the future hold?

To delve deeper into the prostate cancer patient experience over the long term, PCF sat down with Mary-Ellen Taplin, MD, Director of Clinical Research, Lank Center for Genitourinary Oncology Institute, Physician and Associate Professor of Medicine, Harvard Medical School; and PCF’s Medical Director Stuart Holden, MD, Health Sciences Clinical Professor of Urology and Associate Director, UCLA Institute of Urologic Oncology.

Together, Drs. Holden and Taplin have a combined 70 years of experience in urologic oncology treating prostate cancer patients at all stage of disease. They have both seen the trajectory of how medical trends and technological innovations have inexorably and irreversibly altered the way men are diagnosed, treated, and managed.
One thing that hasn’t changed is the years of training required to become a urologic oncologist. After graduating from medical school in 1968, Dr. Holden completed two years of surgery training, followed by two years in the military. He began his training in urology in 1972 and completed it at Memorial Sloan Kettering Cancer Center, having been attracted to the field for its complexity and diversity of cases. “Urology is a fantastic field that encompasses everything: children, the elderly, immunology, and cancer,” said Dr. Holden. “It’s one of the few fields where you can do both medicine and surgery to take care of people. Many of the most seminal discoveries in oncology were introduced to treat urological cancers.”

Dr. Taplin began her research career in cancer immunology in the early 1990s, but began working on prostate cancer (on the androgen receptor) in the laboratory of Dr. Steven Balk. By 1995 she and the team had discovered interesting androgen receptor mutations that became the basis for a *New England Journal of Medicine* article advancing knowledge in prostate cancer treatment resistance.

**The Early Days**

When he began practicing urology in the early 1970s, prostate cancer represented only about 10% of Dr. Holden’s practice. The men who did have prostate cancer were diagnosed in one of three ways: following a transurethral prostatectomy (for the treatment of an enlarged prostate), when a patient presented with metastatic disease (e.g., pain from bone lesions) or during a digital rectal exam, which is part of routine exams today.

In the early days, men who were diagnosed with prostate cancer were treated with surgery, radiation, or “watchful waiting,” now known as active surveillance. But none of these techniques was particularly sophisticated, and there was no way to properly stage the cancer.

Surgery in particular suffered from a lack of knowledge and technique, often to the detriment of the patient. While generally successful in removing the cancerous prostate, surgical procedures were invasive and dangerous, and with a multitude of after effects. “In the old days,” said Dr. Holden, “the operation would take 4-6 hours, and the patient would lose 4-5 units of blood. He would then be hospitalized from anywhere from 10 days to two weeks. Nerve sparing techniques were virtually nonexistent, so men undergoing a radical prostatectomy were guaranteed a complete loss of sexual function, as well as a 5-8% chance of incontinence.” But, as Dr. Holden emphasizes, despite the high complication rate, many patients were rendered cancer-free.

It wasn’t until the 1980s that Dr. Patrick Walsh pioneered a nerve-sparing technique that has become the gold standard for prostate removal. While the “open” operation remained risky for men, especially those of an advanced age, patients were finally afforded a chance to resume a normal, active life following surgery.
The Dawn of the PSA Age

Unfortunately, a general lack of available screening methods meant that by the time many of these men arrived at Dr. Holden’s office, their cancer had advanced beyond the point of cure. This all changed with the introduction of the PSA test in the late 1980s, which led to an explosion of diagnoses and forever changed the face of urology in the United States.

Almost overnight, Dr. Holden’s practice skyrocketed from 10% prostate cancer to a staggering 80%. More impressively, the number of men who presented beyond a curable stage dropped to 5% from an astounding 70%. Clearly the PSA test was something of significance.

These initial results prompted a major push among urologic oncologists to make people aware of prostate cancer and to get a PSA test if appropriate. “Routine screening was a product of the PSA era,” said Dr. Taplin. “If you can feel a tumor during a DRE, generally the cancer is at a later stage. In many ways the PSA test changed all of that.”

The PCF Effect

Despite the many advances that have been made in treating localized prostate cancer, which is now 100% treatable if detected early, roughly 30% of patients will have a poor outcome. PCF was founded precisely for these men, whose aggressive tumors will recur, progress, and metastasize, and whose disease still manages to outsmart even the most sophisticated of therapies.

PCF also played a critical role in driving awareness for prostate cancer during the early years of the PSA era, and these efforts likely contributed to the significant decline in the death rate over the last 20 years. Dr. Holden recalls traveling to Washington, DC, in 1994 with PCF Founder and Chairman Mike Milken and the Reverend Rosey Grier. The trio parked a truck outside of Congress to perform prostate cancer screenings on the National Mall. It was these sorts of guerilla tactics that elevated public awareness of prostate cancer to a level of national discourse.
Where Are We Now?

“The initial treatment options of surgery and radiation have improved and we are more accurate at cancer risk assessment to direct therapy,” said Dr. Taplin. “Radiation is more exact, whereas it used to be crude. With 3D technology and brachytherapy, there are fewer side effects and cure rates are higher.” Research has specifically shown that combining radiation with hormones provides substantial benefits to patients, with a rate of cure that is equal to that of surgery.

For another example, contrast the risk-laden scenario of yesterday’s “open” radical prostatectomies with today’s advanced surgical methods. The “robotic revolution,” which PCF funded in early clinical research in the early 2000s, pioneered a minimally invasive approach to this complex surgery. Today’s so-called “robotic” prostatectomies are performed by a computer-assisted device that is controlled by a surgeon, giving the surgeon better vision and dexterity, allowing the procedure to be performed with greater precision than ever.

Utilizing the latest in robotic technologies, surgery for prostate cancer now takes 2-3 hours with negligible blood loss, and hospital stays have been reduced to 24 hours. Most importantly, robotic prostatectomies carry upwards of 80% nerve-sparing potential, with only a 1-2% risk of serious incontinence. This means that men diagnosed with prostate cancer today can resume a normal lifestyle in ways that were impossible for their predecessors.

“In addition,” said Dr. Holden, “physicians and surgeons have better education and training, and now, everyone in a urologic oncology fellowship...
will train with robots. However, in terms of oncological outcome, the results are the same. But the recovery and quality of life following treatment are better, as is the patient experience in general.”

A major advancement has been improvements in risk stratification, says Dr. Taplin. The ability to identify who is at greatest risk of aggressive disease is a critical step in both curing disease when possible and in improving life after treatment.

Men and their families are more involved in the treatment process than ever before, making the prostate cancer journey a collective family affair. “Men are very engaged these days, more so than in the early 1990s when I started practicing GU oncology. There is so much more information and people are more aware of their choices and they take time to assess these choices,” said Dr. Taplin. “There is much more shared decision making and a focus on education and individualized treatment plans.”

The information available to men with prostate cancer has led to changes in the doctor-patient dynamic. “It’s very important to me to interact with patients, though the Internet has made that more demanding,” said Dr. Holden, referring to the wealth of materials now available online. “I see my job now as a tour guide. I help patients understand what their options are to get the best possible outcome.”

PCF is actively recruiting new research ideas from 19 countries to improve the far earlier detection of aggressive prostate cancer. Much of this effort is in supporting research on the role of genes that turn a normal prostate cell into a cancer cell.

**What Does the Future Hold?**

Dr. Taplin is adamant: PSA testing is useful while we await additional new technologies to catch prostate cancers even earlier. “Patients who are at risk should be screened. The problem with no screening is that it’s bad for men who are most at risk,” she says. Dr. Holden concurs. “The PSA test is not perfect, but it is the best one we have. To throw out the test would risk going back to the old days, and we cannot turn the clock back,” he says.

Now well into his fifth decade as a urologic oncologist, Dr. Holden remains eager to tackle new trends in patient care. First on the list? Precision medicine—the customization of treatment based on a patient’s unique tumor biology—which is poised to revolutionize clinical practice. While exciting, precision medicine represents a new paradigm for cancer care that will require both a new language and a new way of framing clinical evaluations. “There are many new questions that I’ve never considered,” says Dr. Holden. “Such as, how do I incorporate a genetic counselor into my practice?” And while it may take some time to fully realize the extent of its potential and deliver precision medicine to all men with prostate cancer, “it’s definitely the future,” says Dr. Holden.
Dr. Taplin is also optimistic for new developments in therapeutics—specifically, immunotherapies, advanced hormonal approaches, and other targeted therapies that could provide more effective treatment options for men with fewer side effects. She also believes that “liquid biopsies,” simple blood tests that can provide complete tumor DNA profiles, will obviate the need for invasive bone biopsies and bring us closer to true precision medicine.

Achieving these advances will see individual patients as the agents of change, with an increasingly central role in both treatment and scientific discovery. Dr. Taplin stresses the importance of participation in clinical trials in fast-forwarding new treatments and therapies to the clinic. Currently, “not everyone has access [to trials] but they are important to consider where available,” she said. Collaboration between doctors and patients to increase enrollment in clinical trials—especially as we learn more about the genomic complexity of the disease—will be key to realizing game-changing treatments that will benefit all men with prostate cancer.

With all of its promise, the future holds a degree of uncertainty, but both Drs. Holden and Taplin embrace what seems like endless possibility. “Staying abreast of science and understanding can be a burden, but it is rewarding, exciting, and keeps me engaged in a continuous learning process, which reinforces the satisfaction of being a physician/scientist,” said Dr. Holden. “It’s a joy, really.”

“In the old days, we had little to talk about,” says Dr. Holden. “Today we might ask, how do we use all the arrows in the quiver? That’s a good problem to have, and that’s what I tell patients.”

Photography: Paul Bliese

Recent photo of Dr. Holden (8th from left) with PCF’s “Founding Fathers”—a group of researchers that were present at PCF’s very first Scientific Retreat in 1993
MY PROSTATE CANCER STORY

Muhit Rahman | Santa Monica, CA

There is never a convenient time for a prostate cancer diagnosis, and Muhit Rahman of Santa Monica, CA, knows this first-hand. In 2013, just three weeks before running his first marathon, Muhit, who is originally from Bangladesh, learned that he had prostate cancer. The news came as a shock. After all, Muhit was only 57 years old, years away from what is generally considered high-risk. Not only that, but with nearly 10 months of marathon training under his belt, he felt he was in the best shape of his life and healthier than ever.

“It’s always life-altering to hear that you have cancer,” said Muhit, who first became involved with the Prostate Cancer Foundation in 2009 through his work in financial services, years before his diagnosis. “Until you get that news, you don’t have cancer. And then all of a sudden, you do.”

After consulting with his doctors, he determined that his best option, given his age, was a radical prostatectomy. After six weeks of recovery, his doctor gave him the “all clear” to resume his normal activities. But what happened next might surprise you: he started training for another marathon. Just 11 weeks after his surgery, Muhit crossed the finish line at the 2014 LA Marathon, completing the 26.2-mile course in an impressive five hours and 25 minutes. While it wasn’t his best time, he emphasizes with a laugh, it is an accomplishment he recalls with tremendous pride.

Muhit credits his speedy recovery to a newfound commitment to running and a healthy lifestyle. “For me, my cancer diagnosis was the wake-up call, and a reason to get healthy,” he says. “Because of my age, I have a 30% chance of recurrence, and I’m going to do everything I can to beat those odds.”

After the LA Marathon, Muhit prepared for his next challenge: join the 7-continents club. As you might suspect, to join this exclusive roster one must complete a full marathon on each of the seven continents. And yes, that includes Antarctica! Not one to shy away from a challenge, Muhit also vowed to complete all seven races in just seven months’ time. And he achieved that goal. First on the list was Antarctica (“hilly, windy and cold,” he says) in March 2015. Next were Greece and Peru, followed by Kilimanjaro, which he first climbed and then ran with his daughter, in June. Colorado followed in July, and Australia was completed in August. He checked Asia off his list with his completion of the Tazawako Marathon in Japan on September 20th.

Muhit proves that being a prostate cancer survivor is more than simply living a life free of cancer. Quite the opposite—a prostate cancer diagnosis may actually be the beginning of your best, healthiest self. “I got cancer,” says Muhit, “but so what? I’m not going to lie down for it. To hear that you have cancer is terrible, but it is far from the end of the world. It is up to each of us to live our lives—to make the most of each and every day. And I’m doing it!”

““You can almost say that prostate cancer liberated me and freed me to not put things off ... to live life as it is meant to be.”

— Muhit Rahman

Muhit in Antarctica

Photo courtesy Muhit Rahman

You can almost say that prostate cancer liberated me and freed me to not put things off ... to live life as it is meant to be.”

— Muhit Rahman

You can almost say that prostate cancer liberated me and freed me to not put things off ... to live life as it is meant to be.”

— Muhit Rahman

”Muhit in Antarctica

Photo courtesy Muhit Rahman

You can almost say that prostate cancer liberated me and freed me to not put things off ... to live life as it is meant to be.”

— Muhit Rahman

You can almost say that prostate cancer liberated me and freed me to not put things off ... to live life as it is meant to be.”

— Muhit Rahman

You can almost say that prostate cancer liberated me and freed me to not put things off ... to live life as it is meant to be.”

— Muhit Rahman

You can almost say that prostate cancer liberated me and freed me to not put things off ... to live life as it is meant to be.”

— Muhit Rahman

You can almost say that prostate cancer liberated me and freed me to not put things off ... to live life as it is meant to be.”

— Muhit Rahman
Major League Baseball (MLB) and the Prostate Cancer Foundation (PCF) celebrated their 21st season together, a valued partnership that has raised more than $45 million through the MLB-PCF Home Run Challenge. The Home Run Challenge, over its run of 20 Father’s Days, has created hope and awareness for millions of U.S. men.

In 2015 there were 202 home runs hit, raising more than $1.6 million for essential
research resulting in vital medical discoveries. Since its inception, the program has helped to reduce the U.S. prostate cancer death rate by more than 50%.

Joe Torre, MLB Chief Baseball Officer, Hall of Famer and prostate cancer survivor, encouraged fans everywhere to support PCF’s efforts to end prostate cancer by delivering an important public service announcement, “to step up to the plate, help save lives and get one step closer to finding a cure.”

Public Service Announcement created and produced by (add)ventures
Friends of PCF Make a Difference
Leveraging Relationships and Passion into Research Dollars

PCF had a banner year for events in 2015. The Charles Evans PCF Pro-Am Tennis Tour—tournaments in Indian Wells, CA, Greenwich, CT, the Hamptons, NY, and Palm Beach, FL—are popular events scheduled during peak seasons. They provide an exciting and unique experience for amateur players, a platform to introduce new relationships to PCF, and opportunities to raise awareness for prostate cancer and our mission to these communities. The tour raised more than $2 million in 2015.
The capstone of 2015 was our biennial New York City event, held at the Pierre Hotel on December 2nd. The theme was to celebrate PCF’s 20th season partnership with Major League Baseball and its team owners. Baseball luminaries including Joe Torre, Tommy Lasorda, and Tony La Russa attended, along with celebrities Whoopi Goldberg and John O’Hurley. The evening also honored our Philadelphia partners. The event raised more than $2 million.
In addition to the funds raised, the tennis tournaments and the New York dinner resulted in nearly $6 million in new PCF Young Investigator Award commitments. In the past decade, these events have helped finance PCF-funded research that turned into life-extending and life-saving FDA-approved drugs for prostate cancer, as well as 9 other cancers.

Without having affiliate chapters, PCF has established events in key cities throughout each year to meet and share our critical work. Connecting with new audiences in these communities helps raise funds and builds relationships that provide vital support for our most innovative, life-extending research programs.
Since their inception, PCF Special Events have raised more than $131 million for life-saving research.
A SURVIVOR’S APPEAL FOR SUPPORT

“Do you want to live or do you want to die?”

That’s a question Brian Custer asks men, especially African-American men, when they aren’t sure whether to get checked for prostate cancer. As an Emmy Award-winning sports anchor at SportsNet New York (SNY) and host of Showtime Championship Boxing, Custer is known for his affable personality, quick wit and healthy lifestyle. (He has a black belt in taekwondo and trains five times a week.)

Custer is also a prostate cancer survivor. And he’s fearless about raising awareness of the disease and encouraging men to get screened regularly. “Getting checked saved my life. Now, it’s my mission to save lives.

“As men, we have this ego ... we think we’re too macho to go to the doctor and undergo this type of check-up,” says Custer. “But the truth is: If you don’t get checked, you’re cheating your family out of having a husband or father around. And you’re cheating yourself out of life.”

Custer knew something was wrong after his doctor felt a lump on his prostate during a routine screening. “After a few tests, my doctor told me, ‘Brian, you’ve got cancer and it’s very aggressive ... you need surgery as soon as possible.’” That was the summer of 2013. Custer was 42 years old.

At first, Custer questioned whether surgery was the best option. His doctor’s reply was sobering. “Without surgery, you’ll probably die within a year or two.”

Telling his family was hard. Custer and his wife of 14 years, Carmen, have three sons. At the time, the boys were 10, eight and three years old. His middle son asked, “Does this mean you’re going to die?” This crushed Custer.

“I had to give my sons confidence,” he recalls. “I told them, ‘It’s a fight and Daddy’s a fighter. We’re going to be ok.’”

Shortly after, Custer underwent surgery to have his prostate removed. Today he is cancer free and continues to get tested every three months.

For Prostate Cancer Awareness Month in September 2015, Custer partnered with PCF to create a public service announcement about his experience. He believes organizations like PCF are important to increase awareness and connect people to inspiring stories.

“I hope when people hear my story, they’re motivated to take action by saying, ‘I’m going to get checked’ or ‘I’m going to make sure my dad, husband or son gets checked.’”

Brian Custer

Originally published within Prostate & Urological Health campaign by Mediaplanet Publishing House Inc., September 2015
SUPPORTING CURES

There are millions of men currently living with prostate cancer. To support the urgent need for better treatments and cures, the Prostate Cancer Foundation offers individuals and charitable foundations various options for becoming involved and supporting crucial research.

Donations

Please mail your check to:

Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, CA 90401

To make an online contribution, please visit our website www.pcf.org

Blue Ribbon Society

- Join our elite group of recurring donors with an automatic monthly payment using a credit card, debit card or bank account.

Memorial or Tribute Gifts

- Honor the memory of a loved one or celebrate the accomplishments of a friend or family member by helping others with a tribute gift.
- If desired, PCF can also set up a special webpage to honor your loved one and collect donations.

Matching Gifts

- If your company offers an Employee Matching Gifts program, you can make your hard-earned dollars go twice as far with a matching gift to PCF.

Other Gift Suggestions

- Gifts of stock
- Remember PCF in your will.
- Name PCF as a beneficiary of your IRA or life insurance policy.
- Federal employees and retirees participating in the Combined Federal Campaign (CFC) can designate PCF as a beneficiary.

For more information, visit: www.pcf.org/donate

PCF Research Awards

PCF is currently focusing on 3 research priorities:
1. Precision Immunotherapy
2. Precision Medicine
3. New Precision Drug Discovery

PCF advances its research priorities through 3 competitive award types:

Challenge Awards
($1,000,000 and above for 2- to 4-year programs)
Challenge Awards make large investments in multi-year team science projects that have a high potential for delivering new treatments.

Creativity Awards
($300,000 for 2-year programs)
Creativity Awards support the development of high-risk, high-reward ideas from established senior scientists.

Young Investigator Awards
($225,000 for 3-year career investment)
The Young Investigator Awards offer early-career and project support for exceptional investigators (generally 35 and younger) and their ideas, who are committing their lives to the field of prostate cancer. Their institutions match the award dollar-for-dollar.
2015 DONOR ROLL

The support of our generous donors makes all that we do at PCF possible. This honor roll acknowledges actual gifts of $1,000 or more, exclusive of pledges, made to PCF during calendar year 2015. We thank you, our friends and supporters, for your continued commitment to PCF’s mission.

$5,000,000+
- Movember Foundation
- The Stewart J. Rahr Foundation

$1,000,000-$4,999,999
- The Distinguished Gentleman’s Ride
- David H. and Julia Koch
- Mrs. Joyce Stupski

$500,000-$999,999
- Anonymous [2]
- Carl and Gail Icahn
- Janssen R&D/Johnson & Johnson
- Milken Family Foundation
- Stein Erik Hagen Allmennytige Stiftelse
- Elaine Wynn

$250,000-$499,999
- Anonymous [2]
- Astellas Scientific and Medical Affairs
- Peter and Laurie Grauer
- Kern Family Fund
- Richard S. and Karen LeFrak Charitable Foundation
- Merkin Family Foundation, founded by Richard Merkin, MD
- Mr. Brent R. Nicklas
- Paulson Family Foundation
- Roche Translational & Clinical Research Center
- The San Francisco Foundation
- Sanofi-Aventis
- Carl and Gail Icahn
- Anonymous [2]

$150,000-$249,999
- Anonymous
- ASICS America Corporation
- Bayer Corporation
- Todd Boehly
- The Durden Foundation, Inc.
- Mr. Izzy Englelander
- Exosome Diagnostics, Inc.
- Clay and Lynn Hamlin
- Mr. Drew Katz/The Katz Foundation
- Rush Limbaugh
- The Honorable Earle I. and Carol Mack
- Howard and Nancy Marks
- Shmuel Meitar
- Mr. and Mrs. Steven T. Mnuchin
- Mr. Mitchell Modell/Modell’s Inc.
- Arthur and Selma Rabin
- Brian and Patricia Reynolds
- Mr. Nicholas S. Schorsch
- Stephen A. Schwarzman
- Mark and Rosalind Shenkman
- Mr. Alan D. Shortall
- Unlife Medical Solutions Inc.
- J. Eustace Wolftington, III

$100,000-$149,999
- AJA Charitable Fund
- Joseph and Annette Allen
- The Bill and Ann Bresnan Foundation, Inc.
- Steven A. Burd
- Mr. and Mrs. Steven A. Cohen
- Edward P. Evans Foundation
- R. Christian B. Evensen
- Mr. David Farrell
- Astellas Pharma
- Dalia & Larry Leeds/The Leeds Family Foundation
- The McConnell Foundation
- The Neubauer Family Foundation
- Beth Kobliner Shaw and David E. Shaw
- Howard Shore
- Stanley and Barbara Zax

$50,000-$99,999
- Anonymous [2]
- Mark and Debbie Attanasio/Brewers Community Foundation, Inc.
- Reina and Emilio Bassini
- Mrs. Bari Milken Bernstein and Mr. Fred J. Bernstein
- Mr. and Mrs. Seth Bernstein
- David and Allison Blitzer
- Mr. Alan W. Breed
- Jerry and Adrienne Cohen
- James H. Coleman
- Comcast Corporation
- Mr. Michael DeAddio
- Ralph and Cynthia Finerman
- Genomic Health
- John J. and Kiendi Daumphin Gordon Fund
- Joshua J. and Marjorie Harris
- Steven and Maureen Klinsky
- Kolver Family Foundation
- Mr. Pablo Legorreta
- Mr. Gerry Lenfest
- Mr. James Litinsky/Litinsky Family Foundation

Major League Baseball Charities, Inc.
- Bernard Marcus
- Margaretaville Holdings, LLC
- Medical Research Charities
- R.N. Milikowsky Family Foundation
- Millennium Pharmaceuticals, Inc.
- Mr. Anthony D. Minella and Mrs. Sage Minella
- Minnesota Twins
- Dean E. Palin
- The Perper Foundation
- Edward J. & Lorraine E. Primet Trust
- The Republic of Tea
- Cliff and Debbie Robbins and The Robbins Family Foundation
- The Rodin Family Trust
- The Rosenkranz Foundation
- Mr. Jason Safriet
- Sternlicht Family Foundation
- Takeda Pharmaceuticals North America, Inc. & Affiliates
- Mr. Marc D. Taub
- Thomas H. Lee and Ann Tenenbaum
- The Thompson Family Foundation
- Ted and Dani Virtue
- The Wagner Family Foundation
- Kimbra and Mark Walter
- Wolverine Foundation
- WorldQuant Foundation
- Mr. and Mrs. David Yurman

$25,000-$49,999
- Anonymous [3]
- Mr. and Mrs. William A. Ackman
- Ariel Investments
- Ron and Judy Baron
- The Cecile and Fred Bartman Foundation
- Dr. Michael M. Berns and Tricia Berns
- Susan and Jim Blair
- Richard J. Byrne
- Arthur and Eva Byrnes
- Chicago White Sox
- Mr. and Mrs. Adam Cohn
- Robert D. Collins Fund
- Mr. and Mrs. Richard Corcoran
- Neil and Sandra DeFeo Family Foundation
- Desert European Motorcars – Indigo Auto Group
- R.S. Evans Foundation
- Faith, Love, Hope, Win Foundation
- Eugene and Sallyann Fama
- William B. Finneran
- David and Judith Fleischer
- Mr. and Mrs. Michael Gelband
- GenomeDx Biosciences Corp.
- Griffon Corporation
- Mr. and Mrs. Tom Hacker
- Sam Herzberg
- Independence Blue Cross
- Jefferson Kimmel Cancer Center
- David G. Kabiller
- Jerry Katell, Katell Productions, L.L.C.
- Kissick Family Foundation
- Stephanie and Ron Kramer
- Mr. Marc J. Leder
- Mr. George Lucas and Ms. Melody Hobson
- Mr. James Lustig and Mrs. Debbie Lustig
- John & Linda MacDonald Foundation
- Mrs. Jodie Mackintosh
- Mallah Management, LLC
- Mr. Phillip Maloof
- Jerome Meislin
- The Mere Foundation
- Dorothy Philips Michaud Charitable Trust
- Arte and Carole Moreno/The Moreno Family Foundation
- Mr. Rupert Murdoch
- Mr. and Mrs. Glenn Myles
- Mr. Ajay Nagpal and Mrs. Deborah L. Mitchell-Nagpal
- Thomas and Jill Nerney
- James W. Newman
- Newmark & Company Real Estate, Inc.
- David P. Nolan Foundation
- George and Sandra Norcross
- Mr. and Mrs. Henry L. Nordhoff
- Mr. John Novogratz
- Mr. Christian Oberbeck/Lucretius Foundation, Inc.
- Joel M. Pashcow
- Estate of Frances Paulsen
- Sandra and Lawrence Post Family Foundation
- Allan V. Rose
- Ellen and Richard V. Sandler/Richard and Ellen Sandler Family Foundation
- The Mara and Ricky Sandler Foundation
- Mr. Kern W. Schumacher
- Schwartz
- Ms. Edna Shostak
- Mr. and Mrs. Clifford M. Sobel
- The Steele Foundation

$25,000-$49,999
- Anonymous [3]
$15,000-$24,999
Anonymous
Mr. Chris Adams
Robert W. and Deanna Adler
AmeriGas Propane
Robert Bales
Mr. Bill M. Beverage
Blavatnik Family Foundation
Mr. Neil G. Bluhm
Cherotti Family Fund of Akron
Community Foundation
Bethany and Niko Elmahle
Jack Farrell
Mark Finerman
Mr. Glenn Fuhrman
Jeff and Mei Sze Greene
Michelle and Joseph Jacobs
Mr. Bruce A. Karsh
Mr. Jeffrey Karsh
Gerald Katell
Alice Lawrence Foundation, Inc.
Robert Levin/Ashton Distributors
Mr. George Loesch
Donald B Marron Charitable Trust
John and Jana Scarpa – The John F. Scarpa Foundation
Mr. Zachary Schreiber
Lisa and Steven Tananbaum
Family Foundation
Tarnopol Family Foundation, Inc.
Mr. Robert L. Thornton, Jr.
The Robert & Jane Toll Foundation

$10,000-$14,999
Anonymous [3]
Mr. Arthur Agastein
Judd Apatow
Eric Aronsey
The Elias, Genevieve and Georgina Atol Charitable Trust
Beneficial Bank
Martin and Phyllis Berman
Mr. Peter Bren
Mr. and Mrs. David C. Brown, Jr.
Ms. Arlene C. Buechert
Tom Celani
Mr. Michael Cellucci
Mr. and Mrs. Richard Chadakoff
Mr. Edward L. Cohen and Mrs. Debra Cohen
Mr. and Mrs. Eric K. Davidson
Mr. and Mrs. Mickey Drexler
Mark and Sally Ein Foundation
Frank M. Ewing Foundation
Mr. & Mrs. Michael Farrell, Bittmore Family Office
Mr. Jeffrey W. Feldman
Ms. Melody Fleckenstein
Fuente Family Foundation, Inc.
Philip H. Geier, Jr.
Estate of Joseph Gilbert – Joseph Gilbert Admin Trust
Anne K. Gilhuly
Mr. Jay Goldman
Ms. Tricia Gomela
Mr. and Mrs. Thomas F. Herche
Douglas J. Hertz Family Foundation
Lane and Clark Howard, Clark Howard, Inc.
INTECH Construction
David and Janet Kline Fund
James & Frannie Maguire
Mr. and Mrs. Michael Marquart
Frederick W. McCarthy Family Foundation
Memorial Sloan Kettering Cancer Center
Lowell Milken Family Foundation
Lee and Sylvie Millstein
Mr. Jonathan E. Newhouse
Ms. Rama Patel
Mr. Rocky Patel
David Pecker
Deborah and Richard Previdi
Mr. Glenn J. Rufrano
Stephen P. Rust
Mr. David A. Sachs and Mrs. Karen Richards Sach
Mr. Eric P. Salsberg
Mr. and Mrs. David A. Salzman
Satter Foundation
Nancy & Alan Schwartz
Richard and Phyllis Sharlin
Mark J. Simon
Ms. Anne T. Spangenberg
Temple University
Mr. Eric Sugrue
Mr. and Mrs. Harry J. Wild
Wolfington Foundation
Kneeland Youngblood
Loyd and Jeff Zisk

$5,000-$9,999
Anonymous [2]
Dr. Elliot Abramowitz
Acquavella Galleries
Altadis USA, Inc.
Mr. James D. Bagwell
Douglas Berry
Bravelets LLC
Buchanan Ingersoll & Rooneu PC
Ms. Janna Bullock
Cantor Fitzgerald, Inc.
Capital One Services, LLC
Mr. Robert Castellini
CBRE
Gary Charlesworth
Kelly Chung and Kerry Hagen
The Cincinnati Reds Community Fund
Robert and Beverly Cohen Family Foundation
Constellation Energy Group Employee Fund
David and Courtney Corletto
CSC Charitable Foundation
Mr. and Mrs. William Curry
Ms. Ramola Daswani
Mr. and Mrs. Jamie L. Dimon
Durham Family Foundation
Duval and Stachenfeld, LLP.
Stephen Edelmann, Edelmann Family Foundation
David and Marsha Ederer
Falcon Trading Company, Inc.
Dr. Jeffrey Feingold and MCNA Dental
Andrew H. Feinman
Fisheal Family Charitable Foundation
FragranceNet
Mr. Ron Frieman
Alan Gelband
General Cigar Co.
Tamar and Eric Goldstein
Gordon Brothers Group, LLC
John P. Gould and Kathleen A. Carpenter
Grandstand Sports & Memorabilia
Louis and Beth Graziaiodo
Mr. James A. Green
Robert Grossman
Mr. Gordon Gund and Mrs. Lulie Gund
Mr. David Haas
Michelle and Houston Hall Fund of Communities Foundation of Texas
Ms. Julie C. Jaeger
Steve and Janet Kalilal
Mr. and Mrs. David H. Kelsey
Kathleen and Kirk Knous
Stacey and Larry Kohl
Mr. and Mrs. Frank Lawrence
Mr. Mikel A. Lehrman and Mrs. Marcy D. Lehrman
Mr. Richard H. Liem
Mr. Michael Loeb and Mrs. Margie Loeb
Mr. and Mrs. Eric Luse
Lyonnross Capital Management, LLC
Tom Wallace Lyons
Mr. and Mrs. Paul Madura
Mr. William McDaniel
Ms. Susan Miller
William and Nona Morgan
Mr. and Mrs. Michael P. Muldowney
L. Mark Newman Family Foundation
Mr. Robert A. Olstein
Mr. Anthony Orso and Mrs. Amanda Orso
John Paffenbarger
Mr. John E. Pallat, III
Progenics Pharmaceuticals, Inc.
Sharlene and Paul Robe
Mr. Robert Rosenbaum

$2,500-$4,999
Anonymous [6]
The G. Chris Andersen Family Foundation
Mr. John R. D. Angelo
Mr. Jeffrey A. Annenberg
Mr. Michael J. Barton
Mr. William P. Becker and Mrs. Debbie M. Becker
Ms. Sara Begley
Mr. James P. Berg
Mr. Kenneth Bonchek
The Boucher Charitable Foundation
The Caesar Foundation
Ms. Aviva Carmy and Mr. Harry Horowitz
Allen and Jill Chozen
Mr. Kenneth J. Cutillo and Mrs. Lori F. Cutillo
Mr. David DeMuth
Cornelius and Anne Doolan Memorial Fund
Dura-A-Flex Foundation
Ms. Elena L. Eckardt
Mr. Mark D. Emmerson
Mr. Robert Engman and Mrs. Mary Jane Engman
Dr. David Evdokimov
Mr. Neal Ferry
First National Bank in Sioux Falls
Mr. and Mrs. Wayne Giebler
The Gibson Family Foundation
Mr. Irwin N. Gold
Mr. and Mrs. Richard Granville
Ms. Terese S. Guido

Mr. Arnold Rosenshein, III
Marc J. and Carolyn Rowan
Mrs. Mary Ann Rush
Pam and Scott Schafler
Barry K. Schwartz Family Foundation
Stephen and Suzy Shechtman
The Sire Foundation
The Sloan Foundation
Mr. and Mrs. Barry I. Slotnick
Smithburg Family Foundation
Mr. Carl Sparger
Mr. Stephen T. Stairs
Gary Stoneburner
David V.N. Taylor Foundation
Mrs. Judith L. Temple
Mr. and Mrs. Richard Todd
Bruce E. and Robbi S. Toll Foundation
Toyota Motor Credit Corp. – Toyota Financial Services
Jesse I. Treu
Ms. Tanya Tyburski
United Distributors, Inc.
Varhegyi Foundation
Mr. Andrew Whittaker and Mrs. Staphani Whittaker
Art Winkleblack
Mr. Steven Wirth and Mrs. Kathryn Wirth

$2,500-$4,999
Anonymous [6]
Mr. Robert P. Stiller
Roger and Susan Stone
Mr. Chris Tisi
University of Pennsylvania
Valeant Pharmaceuticals
Charles J. Wagner
Mr. and Mrs. Daniel Weingeist
Gregory and Mindy White
Douglas Wood

2015 PROGRESS REPORT | 29 |
$1,000-$2,499

Anonynous [17]
Mr. Dan Abernethy and Mrs. Brenda Abernethy
Aiden and Elizabeth (Bette) Abraham Charitable Gift Fund
Mr. Michael B. Adler and Ms. Michelle Goldberg
Mr. Stanley M. Adler and Mrs. Deborah A. Adler
Mr. and Mrs. David C. Allen
Alpha I Marketing Corp
Mr. and Mrs. Ellsworth C. Alvord, III
Mr. Denis J. Amato and Mrs. Janice Amato
American Medical Systems
Supporting Prostate Heath and Prostate Cancer
Mr. Martin Anaya
Sarah and Markquard Anderson
Arc International North America
Frank J. Arcella
The Asset Preservation Group, Inc.
Dr. Tim A. Auger
Avalonbay Communities
Mr. J. Kent and Dana S. Bailey
Jeffrey and Pamela Balton
Paul Baranay
Norma and Paul Barash
Mr. Michael J. Batza, Jr.
Mr. Thomas E. Beach
Fred Bedard
Mr. and Mrs. Glenn J. Benson
Mr. and Mrs. Charles Berg
Elliott H. Berger
Mr. and Mrs. Barry Berlin
Mr. Byron Bernstein
Best Choice Oil and Gas Tools, Inc.
BGC Legs
Mr. and Mrs. Fred B. Bialek
Mr. Richard Bogomolny and Mrs. Patricia Kozerski
Mr. Herschel Boncheck
Ms. Heidi Borowiecki
Boscow's Department Store, LLC
Mr. Albert R. Boscov
Boutique Blends Cigars LLC
Mr. Jack Brach
Mr. and Mrs. John P. Braislin
Braman & Associates, Inc.
Mr. David Bricker
Mr. Emil J. Britt, Jr.
Mr. Andrew F. Brooks
Gina K. Brourman-Sacks, Leslie Sacks Gallery
Mr. George Brown
David P. and Jerilyn Brownell
Mr. Joseph Cabral
Craig and Caryn Caffarelli
Mr. Bob Campbell
Dr. Joel Canter
Mr. Ian Carnathan
Harvey L. Carter, Ill, MD
Mr. and Mrs. Joseph Wolfington
Mr. Paul K. Zimmerman
Mr. and Mrs. Stephen Chang
Mr. and Mrs. Harvey R. Chaplin
Mr. Paul Chapman
Chapman and Cutler, LLP
Mr. and Mrs. David Check
David and Suzanne Chonette
Mr. and Mrs. James T. Clarke
Mr. Robert Colangelo
Mrs. Christine Cole
William S. Comanor, PhD
Ms. Michelle A. Conlon
Mr. Sean Coogan
Mr. Matthew Cooper
Mr. and Mrs. James W. Corbin, Jr.
Mr. Louis Cortes
Mr. Philip L. Coyne
The Stephen W. Craig Family Foundation
Mr. and Mrs. Neil R. Crowley
Mr. Mike Culwell
Mr. Dominick D'Alleva
Mr. Joseph L. D'Amico
Mr. and Mrs. Richard Danter
Mr. James A. Davidson
Mr. Bruce B. Dayton
Mr. Cosmo DeNicola
Mr. Mark Denton
Mr. Bruce Dereschk
Prof. and Mrs. Michael F. E. Diejomach
Mr. Gerard E. Diffley
Mr. and Mrs. E. James Dixon
Mr. Anthony W. Dona
Dr. and Mrs. James T. Drace
Mr. and Mrs. William E. Dreyer
Michael Dunitz Crisis Foundation
Mrs. Gertrude E. Durand
Mr. Peter J. Durfee
Drs. Ron B. and Anita S. Dutton
Mr. and Mrs. James W. Eggengberger
Lee and Daniele Einsdler
Mr. Daniel M. Elperin
Mr. Andrew R. Fabricant
Mr. and Mrs. Steven J. Farella
Fedway Associates, Inc.
Marita and George Fendelkner
Mr. Brian Feltzin
Mr. and Mrs. Kenneth Field
Mr. and Mrs. Joel B. Finard
Ms. Karen Finerman
Mr. Thomas M. Finke and Mrs. Heather Finke
Mr. Jerome Fiore and Mrs. Terri Curtis
FIS Group
Mrs. Elaine B. Fischer
Ms. Sandra Fitzgerald
Mr. Donald Fleischman and Mrs. Arlene F. Fleischman
Mr. Abraham Flores
Mr. Alan Fodor
Donald Fowlger
Mr. Robert B. Forsland and Mrs. Mary Ann Forsland
Mr. Gerald R. Forsythe
Ms. Jaclyn Frank
Mr. Tommy R. Franks and Mrs. Cathryn C. Franks
Freeport-McMoRan Foundation
Dr. and Mrs. Mark H. Fritz
Frederick and Peggy Furth
Mr. Robin Gates and Ms. Jan Fulwiler
General Bearing Corporation
Mr. and Mrs. Robert Gill
Mr. Dion Giolito
Giuliani Deason Capital Interests, LLC
The Honorable and Mrs. Rudolph W. Giuliani
Mr. Jonathan Glick
Mr. Myles Goldfein
Ltto Gomez
Mr. and Mrs. Jonathan P. Goulding
Mr. Paul D. Green
Mr. Harley Greenfield
Gerry and Herb Greenman
Mark and Merry Grimmett
Mr. Phil Grucci
Dr. Laura Gruskin and Mr. Michael Gruskin
Gurkha Cigar Group, Inc.
Mr. and Mrs. Max Gutierrez, Jr.
Mr. James G. Hammond
Mrs. Douglas S. Hansen
The Hathiwa Family
Mr. and Mrs. Michael C. Haus
Jerry and Marilyn Hayden
HDR
Mr. and Mrs. William H. Healy, Jr.
Mr. Stephen Henderson
William Henry Trust
Mrs. Kathleen May Hensley
Mr. William C. Herman and Mrs. Elizabeth Herman
Mrs. Gisela Hernandez
The Hills of Idaho
Mr. Paul E. Hirschauer
Mr. Bob Hodges
Mr. Patrick Hoene
Mr. Walter M. Holcombe
Dr. and Mrs. Stuart Holden
Mrs. Debra Holstein
The William E. and Audrine C.
Honey Foundation, Inc.
Dr. and Mrs. Leo Nelson Hopkins
Mr. and Mrs. Larry Horn
Mr. and Mrs. Kenneth B. Huggins
Steve Iverson
J.C. Newman Cigar Company
JALS Foundation
Dr. and Mrs. Daryl L. Jesperson
Mr. and Mrs. John Jester
JM Fiber Optics, Inc
Mr. and Mrs. Richard A. Johnson
Mr. and Mrs. Michael Jones
Dr. Ralph T. Jones and Mrs. Sherry Fulwiler
General Bearing Corporation
Mr. and Mrs. Robert Gill
Mr. Dion Giolito
Giuliani Deason Capital Interests, LLC
The Honorable and Mrs. Rudolph W. Giuliani
Mr. Jonathan Glick
Mr. Myles Goldfein
Ltto Gomez
Mr. and Mrs. Jonathan P. Goulding
Mr. Paul D. Green
Mr. Harley Greenfield
Gerry and Herb Greenman
Mark and Merry Grimmett
Mr. Phil Grucci
Dr. Laura Gruskin and Mr. Michael Gruskin
Gurkha Cigar Group, Inc.
Mr. and Mrs. Max Gutierrez, Jr.
Mr. James G. Hammond
Mrs. Douglas S. Hansen
The Hathiwa Family
Mr. and Mrs. Michael C. Haus
Jerry and Marilyn Hayden
HDR
Mr. and Mrs. William H. Healy, Jr.
Mr. Stephen Henderson
William Henry Trust
Mrs. Kathleen May Hensley
Mr. William C. Herman and Mrs. Elizabeth Herman
Mrs. Gisela Hernandez
The Hills of Idaho
Mr. Paul E. Hirschauer
Mr. Bob Hodges
Mr. Patrick Hoene
Mr. Walter M. Holcombe
Dr. and Mrs. Stuart Holden
Mrs. Debra Holstein
The William E. and Audrine C.
Honey Foundation, Inc.
Dr. and Mrs. Leo Nelson Hopkins
Mr. and Mrs. Larry Horn
Mr. and Mrs. Kenneth B. Huggins
Steve Iverson
J.C. Newman Cigar Company
JALS Foundation
Dr. and Mrs. Daryl L. Jesperson
Mr. and Mrs. John Jester
JM Fiber Optics, Inc
Athletes for a Cure
Participants who raised $1,000 or more

Mr. Taylor Burkett
Lida Bunting
Samantha Frank and Jaclyn Frank
Pat Hannon
Mike O’Bryant
Ramiro Siliezar

Special Partnerships and Hosted Events
Special partnerships or hosted events that raised $1,000 or more

2nd Annual AWLG Cornhole Tournament at Crop Production Services in Loveland
6th Annual Deric’s Day at Thunderhill
10th Annual Tom Dawes “We’d Be Fools Not To” Function
11th Annual Turkey Trot – St. Marys, PA
Adrian Fanus Grooming, Inc.
American Medical Systems
Supporting Prostate Heath and Prostate Cancer
Anglers For The Cure
Auburn University’s Alpha Epsilon Chapter of the Alpha Tau Omega Fraternity
AZ State Rifle and Pistol Association – Shotgun Division
Blue Ribbon Clays Tournament
Baseball Heaven, Inc.
The Black Police Association of Greater Dallas
Blowout Biker Productions
Bryant University Pub Hop for Hope

C.A.R.E (Cancer Alzheimer’s Research Event)
Castle Heights Elementary “Steps that Cure”
Chicago Fire Department
Colorado Mule Riders, Inc.
Corpus Christi Yacht Club
Corona-Norco Unified School District – Maintenance Dept.
Deacon Corporation “Staches & Lashes” Event
ExxonMobil Ladies Night Out Group
Groove Phi Groove SFI and William Paterson University students
Pat Hannon’s Tiger Adventure Ride
Harris & Harris, LTD
Kandahar, Afghanistan APO AE 09355 Event
Kearney & Company
Knights of Columbus Don Bosco Council #7784
Lesa Hess’ Kick CANcer to the Curb
LoanCare
Moon Joggers
National Distributing Company Employee Fundraiser
Orange County Imperial Court
Prior Lake – Savage Area Schools
The Redmond Company’s “Blue” Day
Reicher Catholic High School RollerCon, LLC
Saint Tammany Parish Sheriff’s Office
SCW Fitness Education Mania Charity
Simon Says Run for Prostate Cancer
SYSCO Sail Racers to Benefit the Prostate Cancer Foundation
The Xi Chapter of Theta Chi Fraternity
The Employees of UGI Energy Services, LLC
Unified Grocers
The Urban Electric Company’s “Week of Giving”
Urology Central
The Wedding of Lakshmi Mukundan and Harshan Kannan
Wings-Giving at Mudville 9, hosted by Limitless Events NYC

Blue Ribbon Golf Tournaments
Golf tournaments that raised $1,000 or more

8th Annual Pros4Care Golf and Motorcycle Event
5th Annual 19th Hole Classic
Addison Reserve Country Club
Alpha Tau Omega Golf Tournament
American Golf Foundation/ American Golf Corporation
Battle at Columbia Country Club
Battle at Katemaya GC (Cairo, Egypt)
Bella Vista Country Club Golf Tournament
Birdies for Buddies Golf Tournament
Boca Delray Golf
Borg-Warner Shepherd’s Hollow Golf Club
Burlington Golf Club
C.A.R.E Golf Outing
Canoe Brook Country Club
Captain’s Cup at Radagon Hill Golf Club (Ed Griffith Memorial)
Carolina Trace Country Club
A Charity Challenge at Broken Sound, Inc.
The Club at Hidden Creek
Concordia Golf Club
Cottonwood Golf Course
3rd Annual Drive for a Cure at Carmel Mountain Ranch
El Conquistador Golf & Tennis Resort
3rd Annual DIII Father’s Day Golf Tournament (Forest Hills Golf Course)
10th Annual Faith, Love, Hope, Win (FLHW) Golf Tournament
Golfers Against Cancer
H. Smith Richardson Golf Course
Hairy Knuckles at the Strand
Heritage Palms Men’s Niners Golf Club
Herons Glen Golf & Country Club
High Meadows GC
Prostate Partners Golf Tournament (Highland Woods G&CC)
Hilt Texas Shootout
ILWU Tri-Party Challenge
Iron Lakes Country Club
Jay Moody Memorial Golf Tournament
Jonathan’s Landing Golf Club
Joseph DiNapoli, Sr. Memorial Golf Outing
La Crosse Country Club
Lago Vista Golf Course
10th Annual MGA Battle at Lake Spivey GC
Lansing Country Club
Legends Golf & Country Club
Loebster Classic
Luetzow Charity Golf Outing at Stone Links
Lords Valley Country Club
6th Annual W.R. Manese Memorial Golf Tournament
Marlborough CC Women’s Golf
Sadie Hawkins Tourney
Meadow Club
Moose Hunt for the Cure
5th Annual Prostate Cancer Invitational – The Olde Course, Loveland, CO
Palm Aire Country Club
Palm Beach Polo Golf & Country Club
Paupack Hills Golf and Country Club
Pelican Pointe Golf & Country Club
Prostate Partners Golf Tournament (Highland Woods G&CC)
Prostate Partners Golf Tournament (Highland Woods G&CC)
Rarity Bay Golf Club
Rio Verde Country Club
1:31 Sabal Springs Club Charity Golf Tournament
The Sheep
Southfield Silhouettes
Steamboat Springs Golf Club
Steve Hironis Memorial Golf Tournament
Sweetwater Community Men’s Cancer Tournament
Terravita Golf Club
Tiburon Golf Club
Toni Jones Memorial Golf Tournament
University Park Country Club
Wild Dunes Golf Resort
Wycliffe Golf & Country Club (2 events)

Blue Ribbon Society
Our community of monthly donors

Mr. Steve M. Abbott
Mr. Roy E Acer
Ms. Yvette Adams
Mr. Donald Allen
Mr. Norman B. Anti
Mr. and Mrs. M. D. Archer
Col. and Mrs. Jay L. Badger
Mr. Frederick G. Balline
Mr. Louis A. Baldock
Mr. Frank Bicocchi
Mr. Richard O. Boomhower
Mrs. Betty Gene A. Bramley
Mr. Sidney Brandt
Mr. Fern William Bressler
Mr. Robert T. Brew, Jr.
Mr. Kyle E. Brown and Mrs. Jeanette Brown
Mr. and Mrs. Stuart Brown
Ms. Rebecca Brown
Mr. and Mrs. Grant Brown
Mr. Henry L. Burks
Ms. Patricia Burton
Mr. Danny A. Byler
Frank and Adrienne Cardone
Mr. and Mrs. Marvin W. Carlson
Mr. David P. Carosella
Mr. Daniel Chapman
Mr. Scott Chaudhur
Mr. and Mrs. Cory Compton
Mr. and Mrs. Stephen Comnes
Mr. Craig J. Couture
Mr. Jeffery Cundick
Ms. Dorothy Delarm
Mr. James H. Devries
Mr. Todd J. Dokken
Ms. Lark E. Draper
Dr. Steve Dunn
Mr. James A. Dusek
Mr. and Mrs. Willard Easton, Jr.
Mr. Kenneth L. English
Mr. and Mrs. Millison Fambles
Mr. Richard Fournier
Mr. and Mrs. Michael R. Franchio, II
Ms. Jayme Garbo
Mr. and Mrs. John L. Garvin
Mr. Ryan Gilmartin
Mr. Stanley A. Glassman
Mrs. Joyce Gonzales
Mr. Gary M. Goodfriend
Mr. and Mrs. Robert Greenbaum
Gerry and Herb Greenman
Mr. James G. Hammond
Ms. Julie A. Hansen
Mr. Kent L. Hastings and Mrs. Libby Hastings
Mr. Michael L. Hawley and Mrs. Patricia D. Hawley
Mr. Barry L. Heath
Mr. and Mrs. Daniel Henry
Mr. Vincent Heslin
Mr. Bradford L. Hillegass
Mr. Bob Hodges
Mr. and Mrs Michael R. Hund
Mrs. Christine M. Hunter
Ms. Alexandra M. Ivancic
Lt. Luke W. Jean
Mr. Randall John
Mr. and Mrs. Mark W. Johnson
In Memory Tribute Funds
Funds that contributed $1,000 or more

In Memory of:
Carroll Winston Arthur
Edward R. Bardgett
William Brandis Blacklow
Charles J. “Charlie” Bunyan, Jr.
Dr. S. Ward Casscells, Ill
Michael Allan Chernuchin
Bernard Cohen
Stephen S. Cole
Philip Sherburne Constable
Leo Wardle Cooper, Jr.
Richard Rayburn “Ray” Crawford
Moti Daswani
Thomas Dawes
Robert J. “Bob” Dean
Anthony Sebastian “Tony” Dente
Joseph Paul DiNapoli, Sr.
Albert V. Durand
David Emerson
George Robert Flynn
Dan Fogelberg
Pinkney Carroll “P.C.” Froneberger, Ill
Harvey “George” Gangler, Jr.
Robert Thomas Gilhuly
Sanford H. Glassman
Madison B. “Maddy” Graves, II
Douglas S. Hansen
William Harvey
Jerome H. “Jerry” Haus
Scott A. Hawley
Jose “Joe” Hernandez
Arthur Stevenson “Steve” Hirons
Sebastiaan W. Q. “Bas” Hofland
John Hyland, Ill
William L. “Bill” Jaeger
Orville R. Jones
Thomas E. Jones
James Richard “Jim” Klein
Robert Henry Klein
Edward Kondrakci
Theodore Edwin “Ted” Konkle
Christopher A. Krack
Kenneth Kumashiro
Warren H. Luening, Jr.
Frederick G. May, III and Ann L. May
Michael Shaw “Mike” McClaskey
George G. McKiernan
Milton Presley McLeod
Leonard A. Meltzer
Richard Merkle
Steven Millstein
E. Michael “Mike” Moore, Jr.
Padmanabhan “Dan” Mukundan
William A. Mulac
Ralph Osnoss
Robert J. Ott, Sr.
A. Winston Oxlney
Amreek Singh Patal
Naresh Patel
Andrew Paterson
Lyle D. Pauley
Joseph J. Pedotto
Frank A. Poulos
Peter I. Praeger, M.D.
Mark Redmond
Donald Edward Riesbeck
Ronald E. Rokosz
Earl Martin Rush
Frank Rusinko, Jr.
Leslie Joel Sacks
Lloyd Sakakihara
Gordon Jules Sarret
Neve Richard Savage
John Schlimm
Verne M. Spanenberg
Lawrence H. Spector
Lawrence J. Stupski
David L. Sutton
Henry L. Talbert
Michael L. “Mickey” Tarnopol
Judy and Leo Tasse
Timothy B. Taylor
Robert J. Temple
George Voelz
Jay L. Wallberg
Richard Warren
Michael Anthony “Tony” Weigle
Abiatha White
Yoo Up Won
Joseph Woodby
Jeffrey L. Wright, Sr.
William B. “Bill” Yandry
David A. Zarach
Filippo Zarrelli

In Honor Tribute Funds
Funds that contributed $1,000 or more

In Honor of:
Dr. Elliot Abramowitz
The Staff of 21st Century Oncology

Represented annual donations
(gifts, not pledges) between
January 1, 2015 and
December 31, 2015.
2015 RESEARCH AWARDS: EXPANDING PCF’S GLOBAL RESEARCH ENTERPRISE

PCF Young Investigators attended the 22nd Annual PCF Scientific Retreat and shared their unpublished data.

PCF YOUNG INVESTIGATOR AWARDS

The achievements of PCF Young Investigators represent some of the most game-changing work in all of cancer research. They keep the field of prostate cancer research vibrant with new ideas. In 2015, PCF funded 24 new Young Investigators. By mid-year 2015, PCF had funded a total of 178 Young Investigators since the program began.

2015 David H. Koch–PCF Young Investigator Award
Wassim Abida, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY

2015 John A. Paulson–PCF Young Investigator Award
Rahul Aggarwal, MD
University of California, San Francisco, San Francisco, CA

2015 Kelsey Dickson–PCF Young Investigator Award
Heather Cheng, MD, PhD
University of Washington, Seattle, WA

2015 Adrianne and Jerry Cohen–PCF Young Investigator Award
(Funding Year 1 of 3)
Justin Drake, PhD
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

2015 WorldQuant Foundation–PCF Young Investigator Award
Claire Fletcher, PhD

2015 Brent Nicklas–PCF Young Investigator Award
Amanda Hargrove, PhD
Duke University, Durham, NC

2015 Victoria and Vinny Smith–PCF Young Investigator Award
Joseph Ippolito, MD, PhD
Washington University, St. Louis, MO

2015 Neal Rodin–PCF Young Investigator Award
(Funding Year 1 of 3)
Won Kim, MD
University of California, San Francisco, San Francisco, CA
2015 Jerry Lenfest–PCF Young Investigator Award
Vishal Kothari, PhD
University of Michigan, Ann Arbor, MI

2015 Lori Milken–PCF Young Investigator Award
John Kyung Lee, MD
University of California, Los Angeles, Los Angeles, CA

2015 Stephen A. Schwarzman–PCF Young Investigator Award
Zhenfei Li, PhD
Cleveland Clinic Foundation, Cleveland, OH

2015 National Cancer Institute–PCF Young Investigator Award
Ravi Madan, MD
National Cancer Institute, Rockville, MD

2015 John A. Paulson–PCF Young Investigator Award
Sean McGuire, MD, PhD
Baylor College of Medicine, Houston, TX

2015 David Yurman–PCF Young Investigator Award
Rana McKay, MD
Harvard-Dana-Farber Cancer Institute, Boston, MA

2015 Lori Milken–PCF Young Investigator Award
Saul Priceman, PhD
City of Hope National Medical Center, Duarte, CA

2015 John A. Paulson–PCF Young Investigator Award
Yuanyuan Qiao, PhD
University of Michigan, Ann Arbor, MI

2015 Peter T. Grauer–PCF Young Investigator Award
Ashley Ross, MD, PhD
Johns Hopkins University, Baltimore, MD

2015 Kelsey Dickson–PCF Young Investigator Award
Michael Schweizer, MD
University of Washington, Seattle, WA

2015 David Yurman–PCF Young Investigator Award
Shabnam Shalapour, PhD
University of California, San Diego, San Diego, CA

2015 Howard Shore–PCF Young Investigator Award
Prasanna Sooriakumaran, MBBS, PhD

2015 National Cancer Institute–PCF Young Investigator Award
Adam Sowalsky, PhD
National Cancer Institute, Rockville, MD

2015 Genomic Health–PCF Young Investigator Award
Rendong Yang, PhD
University of Minnesota, Minneapolis, MN

2015 James Litinsky–PCF Young Investigator Award
Shuang Zhao, MD
University of Michigan, Ann Arbor, MI

2013 Neil P. DeFeo–PCF Young Investigator Award
(Funding Year 3 of 3)
Li Wang, PhD
Icahn School of Medicine at Mount Sinai, New York, NY

PCF CHALLENGE AWARDS

In 2015, 21 Challenge Award teams were funded by the Foundation. Through peer reviews, PCF selected these projects out of 55 proposals from highly qualified research teams at 43 prestigious cancer centers located in three countries. The Class of 2015 Challenge Awards represents an investment of more than $19 million in advanced prostate cancer research.

2015 Movember Foundation–PCF Challenge Awards

Co-Principal Investigators:
Adam Dicker, MD, PhD
Thomas Jefferson University, Philadelphia, PA
Lawrence Fong, MD, PhD
University of California, San Francisco, San Francisco, CA

Goal: Develop a new combination neoadjuvant therapy for prostate cancer patients that combines a prostate cancer vaccine with radiation therapy

Co-Principal Investigators:
Haojie Huang, PhD
Mayo Clinic, Rochester, MN
Scott Dehm, PhD
University of Minnesota, Minneapolis, MN
Martin Gleave, MD
Vancouver Prostate Centre, Vancouver, BC
Manish Kohli, MD
Mayo Clinic, Rochester, MN

Goal: Develop a novel combination therapy targeting the expression and activity of the androgen receptor to overcome treatment resistance in CRPC

Co-Principal Investigators:
Peter Nelson, MD
Fred Hutchinson Cancer Research Center, Seattle, WA
Philip Kantoff, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Bruce Montgomery, MD
University of Washington, Seattle, WA

Goal: Characterize inherited and acquired DNA damage repair gene mutations found in prostate tumors to determine sensitivity to various therapeutics

Co-Principal Investigators:
Mark Rubin, MD
Weill Cornell Medical College, New York, NY
Scott Tomlins, MD, PhD
University of Michigan, Ann Arbor, MI
Ronglai Shen, PhD
Memorial Sloan Kettering Cancer Center, New York, NY

Goal: Identify molecular mediators of prostate cancer progression that may serve as therapeutic targets and precision medicine biomarkers
Co-Principal Investigators:
Phuoc Tran, MD, PhD
Johns Hopkins University, Baltimore, MD
Theodore DeWeese, MD
Johns Hopkins University, Baltimore, MD
Adam Dicker, MD, PhD
Thomas Jefferson University, Philadelphia, PA
Charles Drake, MD, PhD
Johns Hopkins University, Baltimore, MD
Mario Eisenberger, MD
Johns Hopkins University, Baltimore, MD
Kenneth Pienta, MD
Johns Hopkins University, Baltimore, MD
Martin Pomper, MD, PhD
Johns Hopkins University, Baltimore, MD

Goal: Develop a new treatment combining stereotactic ablative radiation (SABR) with immunotherapy for patients with oligometastatic prostate cancer

Co-Principal Investigators:
Shaomeng Wang, MD
University of Michigan, Ann Arbor, MI
Arul Chinnaiyan, MD, PhD
University of Michigan, Ann Arbor, MI

Goal: Develop a new therapy for CRPC that targets the MLL complex, which regulates the activity of the androgen receptor

Co-Principal Investigators:
Joshua Lang, MD
University of Wisconsin, Madison, WI
David Beebe, PhD
University of Wisconsin, Madison, WI

Goal: Create a novel technology to isolate and study circulating tumor cells as biomarkers for therapeutic responses in clinical trials

2015 PCF Challenge Awards

Dario Altieri, MD
Wistar Institute, Philadelphia, PA

Goal: Elucidate the role of metabolic alterations in tumor metastasis and developing novel therapeutic strategies that target prostate tumor metabolism

Co-Principal Investigators:
David Baltimore, PhD
California Institute of Technology, Pasadena, CA
Owen Witte, MD
University of California, Los Angeles, Los Angeles, CA

Goal: Create a novel T-cell gene therapy for the immunotherapeutic treatment of prostate cancer

Co-Principal Investigators:
William Kevin Kelly, DO
Thomas Jefferson University, Philadelphia, PA
Robert Don, MD
Thomas Jefferson University, Philadelphia, PA
Karen Knudsen, PhD
Thomas Jefferson University, Philadelphia, PA

Goal: Identify biomarkers that predict whether CRPC patients will be more likely to benefit from abiraterone vs. chemotherapy and optimize the duration of chemotherapy treatment

Hing Leung, MBBS, PhD
University of Glasgow, Glasgow, Scotland, U.K.

Goal: Develop strategies to optimize the efficacy of chemotherapy in prostate cancer patients

Co-Principal Investigators:
Paul Nghiem, MD, PhD
University of Washington, Seattle, WA
Peter Nelson, MD
Fred Hutchinson Cancer Research Center, Seattle, WA

Goal: Compare the biology of Merkel cell carcinoma and neuroendocrine prostate cancer to identify new treatment strategies

Co-Principal Investigators:
Ganesh Palapattu, MD
University of Michigan, Ann Arbor, MI
William Kevin Kelly, DO
Thomas Jefferson University, Philadelphia, PA
Karen Knudsen, PhD
Thomas Jefferson University, Philadelphia, PA
David Smith, MD
University of Michigan, Ann Arbor, MI

Goal: Develop a novel immunotherapy by engineering Natural Killer immune cells to target and kill prostate tumor cells

Matthew Rettig, MD
University of California, Los Angeles, Los Angeles, CA

Goal: Optimize strategies to target the MAPK pathway in CRPC patients

PCF’s 2015 Scientific Retreat was held in Washington, DC, October 7-10 and was attended by more than 500 scientists and researchers from 17 countries.
2015 PCF Special Challenge Awards

Arul Chinnaiyan, MD, PhD
University of Michigan, Ann Arbor, MI
Goal: Create a comprehensive molecular characterization of CRPC tumors as they progress over time and in response to treatments

Omid Farokhzad, MD
Harvard: Brigham and Women’s Hospital, Boston, MA
Goal: Develop novel nanotherapies that deliver drugs directly to tumors

Co-Principal Investigators:
Stephen J. Forman, MD
Beckman Research Institute at the City of Hope, Duarte, CA
Saul Priceman, PhD
City of Hope National Medical Center, Duarte, CA
Sumanta Pal, MD
City of Hope National Medical Center, Duarte, CA
Goal: Develop a novel PSCA-targeting CAR T-cell immunotherapy for prostate cancer patients

Martin Gleave, MD
Vancouver Prostate Centre, Vancouver, BC
Goal: Evaluate adaptive pathways of mCRPC and identify an effective combination of inhibitors

Co-Principal Investigators:
Karen Knudsen, PhD
Thomas Jefferson University, Philadelphia, PA
Johan de Bono, MD, PhD
Mark Rubin, MD
Weill Cornell Medical College, New York, NY
Felix Feng, MD
University of California, San Francisco, San Francisco, CA
Goal: Characterize DNA repair gene alterations found in prostate tumors and match patients with appropriate therapies

Co-Principal Investigators:
Christopher Logothetis, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Gary Gallick, PhD
The University of Texas MD Anderson Cancer Center, Houston, TX
Goal: Develop biomarkers that indicate the efficacy and mechanisms of tumor microenvironment-targeting therapies

Edward Schaeffer, MD
Johns Hopkins University, Baltimore, MD
Goal: Develop novel tools for disease stratification

Eric Small, MD
University of California, San Francisco, San Francisco, CA
Goal: Characterize the molecular landscape of CRPC

All attendees present at the 22nd Annual PCF Scientific Retreat on Friday, October 9, 2015

Photography: Paul Bliese
### CONSOLIDATED STATEMENT OF FINANCIAL POSITION

#### December 31

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>2015 Total</th>
<th>2014 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$28,591,542</td>
<td>$</td>
<td>$28,591,542</td>
<td>$29,828,888</td>
</tr>
<tr>
<td>Pledges Receivable (Net)</td>
<td>19,554,663</td>
<td>4,584,000</td>
<td>24,138,663</td>
<td>26,095,145</td>
</tr>
<tr>
<td>Prepaid Expenses and Other Assets</td>
<td>118,578</td>
<td>-</td>
<td>118,578</td>
<td>123,052</td>
</tr>
<tr>
<td>Property and Equipment (Net)</td>
<td>130,304</td>
<td>-</td>
<td>130,304</td>
<td>156,906</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$48,395,087</td>
<td>$4,584,000</td>
<td>$52,979,087</td>
<td>$56,203,991</td>
</tr>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts Payable</td>
<td>$263,203</td>
<td>$</td>
<td>$263,203</td>
<td>$1,139,495</td>
</tr>
<tr>
<td>Accrued Liabilities</td>
<td>1,309,901</td>
<td>-</td>
<td>1,309,901</td>
<td>988,542</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>300,000</td>
<td>-</td>
<td>300,000</td>
<td>400,000</td>
</tr>
<tr>
<td>Grants Payable</td>
<td>21,355,345</td>
<td>-</td>
<td>21,355,345</td>
<td>21,907,606</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>$23,228,449</td>
<td>-</td>
<td>$23,228,449</td>
<td>$24,435,643</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>25,166,638</td>
<td>-</td>
<td>25,166,638</td>
<td>26,948,348</td>
</tr>
<tr>
<td>Temporarily Restricted</td>
<td>-</td>
<td>4,584,000</td>
<td>4,584,000</td>
<td>4,820,000</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td>25,166,638</td>
<td>4,584,000</td>
<td>29,750,638</td>
<td>31,768,348</td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td>$48,395,087</td>
<td>$4,584,000</td>
<td>$52,979,087</td>
<td>$56,203,991</td>
</tr>
</tbody>
</table>
# CONSOLIDATED STATEMENT OF ACTIVITIES

**Year Ended December 31**

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>2015 Total</th>
<th>2014 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue and Public Support</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants and Contributions</td>
<td>$36,463,944</td>
<td>$4,584,000</td>
<td>$41,047,944</td>
<td>$41,332,776</td>
</tr>
<tr>
<td>Interest and Dividends</td>
<td>51,342</td>
<td></td>
<td>51,342</td>
<td>36,488</td>
</tr>
<tr>
<td>Other</td>
<td>(76,401)</td>
<td></td>
<td>(76,401)</td>
<td>(142,265)</td>
</tr>
<tr>
<td>Net Assets Released from Purpose Restrictions</td>
<td>4,820,000</td>
<td>(4,820,000)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Revenue and Public Support</strong></td>
<td>$41,258,885</td>
<td>(236,000)</td>
<td>$41,022,885</td>
<td>$41,226,999</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program Services:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Grants</td>
<td>26,933,248</td>
<td></td>
<td>26,933,248</td>
<td>31,727,332</td>
</tr>
<tr>
<td>Compensation, Benefits, and Payroll Taxes</td>
<td>2,763,999</td>
<td></td>
<td>2,763,999</td>
<td>2,732,603</td>
</tr>
<tr>
<td>Global Scientific Conferences, Unpublished Data, and Knowledge Exchanges</td>
<td>1,918,386</td>
<td></td>
<td>1,918,386</td>
<td>2,191,332</td>
</tr>
<tr>
<td>Media, Public Relations, and Publications</td>
<td>1,864,186</td>
<td></td>
<td>1,864,186</td>
<td>602,823</td>
</tr>
<tr>
<td>Professional Fees</td>
<td>813,079</td>
<td></td>
<td>813,079</td>
<td>838,424</td>
</tr>
<tr>
<td>Outreach, Events, and Meetings</td>
<td>537,496</td>
<td></td>
<td>537,496</td>
<td>647,055</td>
</tr>
<tr>
<td>Travel, Meals, and Entertainment</td>
<td>228,372</td>
<td></td>
<td>228,372</td>
<td>148,201</td>
</tr>
<tr>
<td>Office Expenses</td>
<td>225,212</td>
<td></td>
<td>225,212</td>
<td>320,144</td>
</tr>
<tr>
<td>Occupancy</td>
<td>117,236</td>
<td></td>
<td>117,236</td>
<td>133,389</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>46,126</td>
<td></td>
<td>46,126</td>
<td>114,496</td>
</tr>
<tr>
<td><strong>Total Program Services:</strong></td>
<td>$35,447,340</td>
<td></td>
<td>$35,447,340</td>
<td>$39,455,799</td>
</tr>
<tr>
<td><strong>Supporting Services:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and General:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compensation, Benefits, and Payroll Taxes</td>
<td>1,321,694</td>
<td></td>
<td>1,321,694</td>
<td>1,458,279</td>
</tr>
<tr>
<td>Office Expenses</td>
<td>551,846</td>
<td></td>
<td>551,846</td>
<td>507,068</td>
</tr>
<tr>
<td>Professional Fees</td>
<td>284,691</td>
<td></td>
<td>284,691</td>
<td>363,176</td>
</tr>
<tr>
<td>Occupancy</td>
<td>202,695</td>
<td></td>
<td>202,695</td>
<td>188,120</td>
</tr>
<tr>
<td>Travel, Meals, and Entertainment</td>
<td>45,881</td>
<td></td>
<td>45,881</td>
<td>21,590</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>33,187</td>
<td></td>
<td>33,187</td>
<td>31,653</td>
</tr>
<tr>
<td>Other Expenses</td>
<td>-</td>
<td></td>
<td>-</td>
<td>450,000</td>
</tr>
<tr>
<td><strong>Total Management and General:</strong></td>
<td>$2,439,994</td>
<td></td>
<td>$2,439,994</td>
<td>$3,019,886</td>
</tr>
<tr>
<td><strong>Fundraising:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outreach, Events, and Meetings</td>
<td>3,039,745</td>
<td></td>
<td>3,039,745</td>
<td>2,092,239</td>
</tr>
<tr>
<td>Travel, Meals, and Entertainment</td>
<td>721,173</td>
<td></td>
<td>721,173</td>
<td>945,874</td>
</tr>
<tr>
<td>Compensation, Benefits and Payroll Taxes</td>
<td>720,216</td>
<td></td>
<td>720,216</td>
<td>1,117,196</td>
</tr>
<tr>
<td>Office Expenses</td>
<td>327,263</td>
<td></td>
<td>327,263</td>
<td>358,878</td>
</tr>
<tr>
<td>Professional Fees</td>
<td>271,672</td>
<td></td>
<td>271,672</td>
<td>217,976</td>
</tr>
<tr>
<td>Occupancy</td>
<td>57,380</td>
<td></td>
<td>57,380</td>
<td>40,097</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>15,812</td>
<td></td>
<td>15,812</td>
<td>9,600</td>
</tr>
<tr>
<td><strong>Total Fundraising:</strong></td>
<td>$5,153,261</td>
<td></td>
<td>$5,153,261</td>
<td>$4,782,860</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$43,040,595</td>
<td></td>
<td>$43,040,595</td>
<td>$47,258,545</td>
</tr>
<tr>
<td><strong>Change in Net Assets</strong></td>
<td>(1,781,710)</td>
<td>(236,000)</td>
<td>(2,017,710)</td>
<td>(6,031,546)</td>
</tr>
<tr>
<td>Net Assets – Beginning of Year</td>
<td>26,948,348</td>
<td>4,820,000</td>
<td>31,768,348</td>
<td>37,799,894</td>
</tr>
<tr>
<td><strong>Net Assets – End of Year</strong></td>
<td>$25,166,638</td>
<td>$4,584,000</td>
<td>$29,750,638</td>
<td>$31,768,348</td>
</tr>
</tbody>
</table>
## CONSOLIDATED STATEMENT OF CASH FLOWS

<table>
<thead>
<tr>
<th>Year Ended December 31</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in Net Assets</td>
<td>$(2,017,710)</td>
<td>$(6,031,546)</td>
</tr>
<tr>
<td><strong>Adjustments to Reconcile Change in Net Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>to Net Cash Provided by (Used In) Operating Activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncollectible Pledges Receivable</td>
<td>-</td>
<td>450,000</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>95,125</td>
<td>155,749</td>
</tr>
<tr>
<td>(Increase) Decrease in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pledges Receivable</td>
<td>1,956,482</td>
<td>1,666,615</td>
</tr>
<tr>
<td>Prepaid Expenses and Other Assets</td>
<td>4,474</td>
<td>(591)</td>
</tr>
<tr>
<td>Increase (Decrease) in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts Payable</td>
<td>(876,292)</td>
<td>928,403</td>
</tr>
<tr>
<td>Accrued Liabilities</td>
<td>321,359</td>
<td>(271,766)</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>(100,000)</td>
<td>(100,000)</td>
</tr>
<tr>
<td>Grants Payable</td>
<td>(552,261)</td>
<td>3,845,176</td>
</tr>
<tr>
<td><strong>Net Cash Provided by (Used In) Operating Activities</strong></td>
<td>$(1,168,823)</td>
<td>642,040</td>
</tr>
<tr>
<td><strong>CASH FLOWS USED IN INVESTING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of Property and Equipment</td>
<td>(68,523)</td>
<td>(69,566)</td>
</tr>
<tr>
<td><strong>Net Increase (Decrease) in Cash and Cash Equivalents</strong></td>
<td>(1,237,346)</td>
<td>572,474</td>
</tr>
<tr>
<td>Cash and Cash Equivalents – Beginning of Year</td>
<td>29,828,888</td>
<td>29,256,414</td>
</tr>
<tr>
<td><strong>Cash and Cash Equivalents – End of Year</strong></td>
<td>$28,591,542</td>
<td>$29,828,888</td>
</tr>
</tbody>
</table>
INDEPENDENT AUDITOR’S REPORT

To the Board of Directors
Prostate Cancer Foundation

Report on the Consolidated Financial Statements
We have audited the accompanying consolidated financial statements of the Prostate Cancer Foundation, which comprise the consolidated statement of financial position as of December 31, 2015, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Prostate Cancer Foundation as of December 31, 2015, and the changes in its consolidated net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Report on Summarized Comparative Information
We have previously audited Prostate Cancer Foundation’s 2014 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated June 9, 2015. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2014 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Green Hasson & Janks LLP

April 26, 2016
Los Angeles, California
PCF is grateful for our corporate supporters. Contributions and campaigns from these organizations are enabling PCF to move closer to a world without prostate cancer.
BOARD OF DIRECTORS AND LEADERSHIP TEAM

Board of Directors

Michael Milken  
Founder and Chairman  
Prostate Cancer Foundation

Andrew J. Astrachan  
Chief Executive Officer  
Onyx Partners, Inc.

Emilio Bassini  
Managing Principal  
Bassini & Company

J. Darius Bikoff  
Founder  
The Observatory US, Inc.

James C. Blair, PhD  
Partner  
Domain Associates, LLC

Steven A. Burd  
Founder and Chief Executive Officer  
Burd Health LLC

Neil P. DeFeo  
Former Founder and Chairman  
Sun Products Corporation

David A. Ederer  
Chairman  
Ederer Investment Company

R. Christian B. Evensen  
Managing Partner  
Flintridge Capital Investments, LLC

Peter T. Grauer  
Chairman  
Bloomberg LP

The Reverend Rosey Grier  
Milken Family Foundation

Stuart Holden, MD  
Clinical Professor of Urology  
David Geffen School of Medicine,  
Spielberg Family Chair of Urologic Oncology,  
Associate Director, UCLA Institute of Urologic Oncology

Clark Howard  
Syndicated TV and Radio Host

Arthur H. Kern  
Investor

David H. Koch  
Executive Vice President  
Koch Industries, Inc.

Richard S. LeFrak  
Chairman and Chief Executive Officer  
LeFrak Organization

The Honorable Earle I. Mack  
Senior Partner  
The Mack Company

Shmuel Meitar  
Chairman and Founder  
Aurec Capital

Lori Milken  
Vice President  
Prostate Cancer Foundation

Glenn Myles  
Chief Executive Officer  
First Wall Street Family Office

Henry L. Nordhoff  
Chairman and Chief Executive Officer  
Banyan Biomarkers, Inc.

Drew Pinsky, MD  
Internist, Addictionologist, Assistant Clinical Professor, Psychiatry  
University of Southern California Radio and Television Host

Lynda Resnick  
Vice Chairman  
The Wonderful Company

Neal I. Rodin  
Managing Director  
International Financial Company

Leadership Team

Jonathan W. Simons, MD  
President and Chief Executive Officer  
David H. Koch Chair

Ralph Finerman  
Chief Financial Officer, Treasurer and Secretary

Howard R. Soule, PhD  
Executive Vice President, Chief Science Officer

Barbara J. Parsky  
Senior Vice President, Chief Marketing Officer

Stuart Holden, MD  
Medical Director

Philip W. Kantoff, MD  
Chairman  
Global Research Council Chairman  
Global Treatment Sciences Network  
George J. Bosi Chair in Medicine, Memorial Sloan Kettering Cancer Center

Helen Hsieh  
Senior Vice President Finance and Administration

Roger Castle  
Vice President Development

Jan Haber  
Vice President Events
Andrew “Andy” Grove
1936 – 2016

PCF celebrates the life and contributions of Andy Grove. As a PCF Board Director, Andy not only gave philanthropically, but also provided intellectual guidance and public advocacy to accelerate life-saving research. He was an inspiration and friend to young prostate cancer scientists working in the genomic age.